2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:Ta0d,To compare 1-year changes in estimated 10-year and lifetime atherosclerotic cardiovascular disease (ASCVD) risk following metabolic and bariatric surgery (MBS) versus glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy among adults with obesity. Obesity is a major driver of ASCVD through adverse metabolic and inflammatory pathways. Metabolic and bariatric surgery and GLP-1 receptor agonists represent the most effective contemporary treatments for obesity and are increasingly used to mitigate cardiovascular risk. However, their comparative effects on integrated short-term and lifetime ASCVD risk in real-world clinical practice remain incompletely characterized. We conducted a retrospective cohort study of adults with obesity (body mass index ≥30 kg/m²) who underwent MBS or initiated GLP-1RA therapy between 2020 and 2023 within a large tertiary health care system in the United States. Participants were identified from electronic health records and followed for 12 months. Primary outcomes were 1-year changes in estimated 10-year and lifetime ASCVD risk. Secondary outcomes included percent total body weight loss, blood pressure, and lipid parameters. Multivariable linear regression models were used to adjust for baseline body mass index and baseline ASCVD risk. The final cohort included 812 patients, of whom 579 underwent MBS and 233 initiated GLP-1RA therapy. At baseline, patients receiving GLP-1RAs were older and had higher estimated ASCVD risk. At 1 year, reductions in 10-year ASCVD risk were similar between groups (-0.8% vs. -1.1%; P=.36). In contrast, lifetime ASCVD risk decreased significantly more following MBS than GLP-1RA therapy (-8.6% vs. -1.7%; P<.001). MBS was associated with greater percent total body weight loss (-27.8% vs. -11.1%; P<.001) and more favorable lipid changes, including larger reductions in low-density lipoprotein cholesterol and greater increases in high-density lipoprotein cholesterol. After adjustment, MBS remained independently associated with a greater reduction in lifetime ASCVD risk compared with GLP-1RA therapy (β -6.92; 95% CI -9.22 to -4.62). In this real-world cohort, both MBS and GLP-1RA therapy were associated with improvements in estimated cardiovascular risk, but MBS conferred substantially greater reductions in lifetime ASCVD risk, accompanied by superior weight loss and lipid improvements. These findings highlight the complementary roles of surgical and pharmacologic therapies in obesity management and may inform strategies to optimize long-term cardiovascular risk reduction.31:Te42, Objective: To compare 1-year changes in estimated 10-year and lifetime atherosclerotic cardiovascular disease (ASCVD) risk following metabolic and bariatric surgery (MBS) versus glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy among adults with obesity. Summary Background Data: Obesity is a major driver of ASCVD through adverse metabolic and inflammatory pathways. Metabolic and bariatric surgery and GLP-1 receptor agonists represent the most effective contemporary treatments for obesity and are increasingly used to mitigate cardiovascular risk. However, their comparative effects on integrated short-term and lifetime ASCVD risk in real-world clinical practice remain incompletely characterized. Methods: We conducted a retrospective cohort study of adults with obesity (body mass index ≥30 kg/m²) who underwent MBS or initiated GLP-1RA therapy between 2020 and 2023 within a large tertiary health care system in the United States. Participants were identified from electronic health records and followed for 12 months. Primary outcomes were 1-year changes in estimated 10-year and lifetime ASCVD risk. Secondary outcomes included percent total body weight loss, blood pressure, and lipid parameters. Multivariable linear regression models were used to adjust for baseline body mass index and baseline ASCVD risk. Results: The final cohort included 812 patients, of whom 579 underwent MBS and 233 initiated GLP-1RA therapy. At baseline, patients receiving GLP-1RAs were older and had higher estimated ASCVD risk. At 1 year, reductions in 10-year ASCVD risk were similar between groups (−0.8% vs. −1.1%; P =.36). In contrast, lifetime ASCVD risk decreased significantly more following MBS than GLP-1RA therapy (−8.6% vs. −1.7%; P <.001). MBS was associated with greater percent total body weight loss (−27.8% vs. −11.1%; P <.001) and more favorable lipid changes, including larger reductions in low-density lipoprotein cholesterol and greater increases in high-density lipoprotein cholesterol. After adjustment, MBS remained independently associated with a greater reduction in lifetime ASCVD risk compared with GLP-1RA therapy (β −6.92; 95% CI −9.22 to −4.62). Conclusions: In this real-world cohort, both MBS and GLP-1RA therapy were associated with improvements in estimated cardiovascular risk, but MBS conferred substantially greater reductions in lifetime ASCVD risk, accompanied by superior weight loss and lipid improvements. These findings highlight the complementary roles of surgical and pharmacologic therapies in obesity management and may inform strategies to optimize long-term cardiovascular risk reduction. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Metabolic and Bariatric Surgery: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Metabolic and Bariatric Surgery (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Metabolic%20and%20Bariatric%20Surgery\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Metabolic and Bariatric Surgery\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Metabolic%20and%20Bariatric%20Surgery\"}]}}"}}]],["$","$L2f",null,{"title":"Metabolic and Bariatric Surgery: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Metabolic and Bariatric Surgery — concise summaries and practical next steps.","papers":[{"doi":"10.1002/oby.70289","pmid":"42638036","title":"Extreme Obesity (\n BMI\n ≥ 60 kg/m\n ²\n ) Characterization up to and Beyond 80 kg/m\n ²\n in 1,262,454 Bariatric Surgery Patients","journal_title":"Obesity","journal_issn":"1930-7381","published_at":"2026-08-24T00:00:00.000Z","url":"https://doi.org/10.1002/oby.70289","source_score":18,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-01T06:21:02.562Z","updated_at":"2026-09-01T06:21:02.562Z","tags":[{"paper_doi":"10.1002/oby.70289","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"category","value":"Endocrinology & Metabolism","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"condition","value":"Chronic Obstructive Pulmonary Disease","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"condition","value":"Extreme Obesity","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"condition","value":"Hypertension","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"condition","value":"Morbid Obesity","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"condition","value":"Obstructive Sleep Apnea","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"modality","value":"Metabolic and Bariatric Surgery","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"sample_size","value":"n=1795127","value_numeric":1795127},{"paper_doi":"10.1002/oby.70289","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"warning","value":"Brand/generic drug tags omitted — this study focuses on surgical intervention, not pharmacotherapy.","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"warning","value":"Level of evidence assigned as 3 based on large registry cross-sectional design; no randomization or longitudinal follow-up beyond 30 days.","value_numeric":null},{"paper_doi":"10.1002/oby.70289","tag_type":"warning","value":"The eligible analytic sample used for the primary comparisons was n=1,262,454, while the full MBSAQIP dataset contained 1,795,127 patients; the difference likely reflects exclusions not fully detailed in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Cross-sectional analysis of 1,795,127 MBSAQIP registry patients (2015–2023) comparing preoperative comorbidity burden and 30-day outcomes across six BMI categories (< 40 to ≥ 80 kg/m²), with emphasis on extreme obesity (BMI ≥ 60 kg/m²).","key_result":"Extreme obesity (BMI ≥ 60) affected 5.3% of the sample; BMI ≥ 70 was present in 1.1% annually (~1,520 cases/year). Compared to BMI < 40, patients with BMI ≥ 70 had higher rates of hypertension (56.7% vs. 46.9%), sleep apnea (59.6% vs. 34.6%), and functional dependence (4.5% vs. 0.5%). Serious complications rose from 0.7% to 2.6% and mortality from 0.05% to 0.35% at the highest BMI category (both p < 0.001).","limitations":"- Cross-sectional design limits causal inference and long-term outcome assessment beyond 30 days.\n- Registry data may have incomplete or inconsistently recorded comorbidity fields.\n- No comparator group of non-surgical management, so relative risk of surgery vs. no surgery cannot be assessed.","practice_takeaway":"Even at extreme BMIs, absolute 30-day complication and mortality rates remain low and should not preclude bariatric surgery referral. Pre-operative strategies to reduce BMI in patients with BMI ≥ 70 kg/m² deserve prospective evaluation."}},{"doi":"10.1016/j.surg.2026.110492","pmid":"42623901","title":"Drugs are not cutting it: Patient motivations for metabolic and bariatric surgery despite glucagon-like peptide-1 use","journal_title":"Surgery","journal_issn":"0039-6060","published_at":"2026-07-30T00:00:00.000Z","url":"https://doi.org/10.1016/j.surg.2026.110492","source_score":6,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-23T07:33:05.701Z","updated_at":"2026-08-23T07:33:05.701Z","tags":[{"paper_doi":"10.1016/j.surg.2026.110492","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.surg.2026.110492","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1016/j.surg.2026.110492","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.1016/j.surg.2026.110492","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.surg.2026.110492","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.surg.2026.110492","tag_type":"modality","value":"GLP-1 Receptor Agonist","value_numeric":null},{"paper_doi":"10.1016/j.surg.2026.110492","tag_type":"modality","value":"Metabolic and Bariatric Surgery","value_numeric":null},{"paper_doi":"10.1016/j.surg.2026.110492","tag_type":"sample_size","value":"n=14","value_numeric":14},{"paper_doi":"10.1016/j.surg.2026.110492","tag_type":"study_design","value":"Qualitative Study","value_numeric":null},{"paper_doi":"10.1016/j.surg.2026.110492","tag_type":"warning","value":"All participants had already decided to pursue surgery, introducing substantial selection bias; motivations of patients who stayed on GLP-1 RAs are not captured.","value_numeric":null},{"paper_doi":"10.1016/j.surg.2026.110492","tag_type":"warning","value":"No brand or generic drug names were specified in the paper; GLP-1 agents are referred to collectively as 'novel GLP-1 receptor agonists.'","value_numeric":null},{"paper_doi":"10.1016/j.surg.2026.110492","tag_type":"warning","value":"Only 14 participants from a single institution — themes may not generalize to broader or more diverse populations.","value_numeric":null}],"summaries":{"what_studied":"Qualitative study of 14 adult patients with prior or current GLP-1 receptor agonist use who chose to proceed with primary metabolic and bariatric surgery (MBS), using semi-structured interviews to identify motivations for transitioning to surgery.","key_result":"Six themes drove patients toward MBS despite GLP-1 RA use: (1) preference for long-term, durable treatment; (2) desire to reduce comorbidities and health risks; (3) adverse aspects of prior treatments (e.g., GLP-1 side effects); (4) barriers to treatment access (including insurance); (5) social influences; and (6) differences in health care support systems.","limitations":"Very small sample (n=14) from a single institution limits generalizability. Qualitative design captures themes but not prevalence or effect sizes. Selection bias is likely, as participants had already decided on surgery.","practice_takeaway":"When managing patients on GLP-1 receptor agonists, clinicians should proactively discuss MBS as a complementary or alternative option — durability, side effect burden, and access barriers are key drivers of patient preference for surgery. Shared decision-making conversations should address all modalities."}},{"doi":"10.1016/j.amjsurg.2026.117102","pmid":"42323266","title":"The years-of-life advantage of metabolic and bariatric surgery in advanced kidney disease","journal_title":"The American Journal of Surgery","journal_issn":"0002-9610","published_at":"2026-06-16T00:00:00.000Z","url":"https://doi.org/10.1016/j.amjsurg.2026.117102","source_score":5,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-27T13:27:44.207Z","updated_at":"2026-06-27T13:27:44.207Z","tags":[{"paper_doi":"10.1016/j.amjsurg.2026.117102","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.amjsurg.2026.117102","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1016/j.amjsurg.2026.117102","tag_type":"condition","value":"Chronic Kidney Disease","value_numeric":null},{"paper_doi":"10.1016/j.amjsurg.2026.117102","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.1016/j.amjsurg.2026.117102","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.amjsurg.2026.117102","tag_type":"modality","value":"Metabolic and Bariatric Surgery","value_numeric":null},{"paper_doi":"10.1016/j.amjsurg.2026.117102","tag_type":"study_design","value":"Observational Study","value_numeric":null},{"paper_doi":"10.1016/j.amjsurg.2026.117102","tag_type":"warning","value":"Only bibliographic metadata was provided — no abstract, methods, results, or discussion text was available. All summary content reflects only what can be reasonably inferred from the title and journal context. Key quantitative findings, study design specifics, sample size, and follow-up duration could not be extracted or verified.","value_numeric":null},{"paper_doi":"10.1016/j.amjsurg.2026.117102","tag_type":"warning","value":"Publication date is June 2026, which is recent; this paper may not yet be widely indexed or peer-reviewed in full.","value_numeric":null},{"paper_doi":"10.1016/j.amjsurg.2026.117102","tag_type":"warning","value":"The impact_flag 'practice_changing' is tentative — the full results and effect sizes are not confirmed from the available metadata.","value_numeric":null},{"paper_doi":"10.1016/j.amjsurg.2026.117102","tag_type":"warning","value":"The study_design tag is uncertain; 'Observational Study' is a reasonable inference given the topic, but the actual design (e.g., retrospective cohort, database analysis, RCT) is unknown.","value_numeric":null}],"summaries":{"what_studied":"This study evaluated the survival benefit (years-of-life gained) associated with metabolic and bariatric surgery (MBS) in patients with advanced kidney disease, compared to non-surgical management.","key_result":"Metabolic and bariatric surgery was associated with a years-of-life advantage in patients with advanced kidney disease, though specific absolute numbers (e.g., mean years gained, hazard ratios) are not available from the provided abstract.","limitations":"Full text not provided; specific methodology, sample size, follow-up duration, and confounding control details cannot be verified from the available metadata alone.","practice_takeaway":"For patients with advanced kidney disease and obesity, metabolic and bariatric surgery may confer a meaningful survival advantage and should be considered in multidisciplinary care planning. Clinicians should weigh surgical risk against the potential years-of-life benefit in this high-risk population."}},{"doi":"10.1097/sla.0000000000007064","pmid":"42002851","title":"Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy","journal_title":"Annals of Surgery","journal_issn":"0003-4932","published_at":"2026-04-20T00:00:00.000Z","url":"https://doi.org/10.1097/sla.0000000000007064","source_score":85,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-04-25","doi":"10.1097/sla.0000000000007064","days":"30","issn":"0003-4932","rank":"3","field":"Clinical Medicine","score":"85","category":"Surgery","categories":["Surgery"],"_categories":["Surgery"]},"pubmed":{"doi":"10.1097/SLA.0000000000007064","title":"Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy: A Head-to-Head Comparison in Improvement of Cardiometabolic Risk Profiles.","journal":"Annals of surgery","methods":"","results":"The final cohort included 812 patients, of whom 579 underwent MBS and 233 initiated GLP-1RA therapy. At baseline, patients receiving GLP-1RAs were older and had higher estimated ASCVD risk. At 1 year, reductions in 10-year ASCVD risk were similar between groups (-0.8% vs. -1.1%; P=.36). In contrast, lifetime ASCVD risk decreased significantly more following MBS than GLP-1RA therapy (-8.6% vs. -1.7%; P<.001). MBS was associated with greater percent total body weight loss (-27.8% vs. -11.1%; P<.001) and more favorable lipid changes, including larger reductions in low-density lipoprotein cholesterol and greater increases in high-density lipoprotein cholesterol. After adjustment, MBS remained independently associated with a greater reduction in lifetime ASCVD risk compared with GLP-1RA therapy (β -6.92; 95% CI -9.22 to -4.62).","abstract":"$30","keywords":["GLP-1RA","MBS","obesity","semaglutide","tirzepatide"],"pubmed_id":"42002851","conclusions":"","publication_date":"2026-04-20T00:00:00"},"crossref":{"DOI":"10.1097/sla.0000000000007064","URL":"https://doi.org/10.1097/sla.0000000000007064","ISSN":["0003-4932","1528-1140"],"link":[{"URL":"https://journals.lww.com/10.1097/SLA.0000000000007064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy"],"author":[{"given":"Wissam","family":"Ghusn","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"},{"name":"Department of Internal Medicine, Boston University, Boston, MA, USA"}]},{"given":"Robert A.","family":"Vierkant","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA"}]},{"given":"Noura","family":"Jawhar","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic, Rochester, MN, USA"}]},{"given":"Tala","family":"Abedalqader","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic, Rochester, MN, USA"}]},{"given":"Nour","family":"El Ghazal","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic, Rochester, MN, USA"}]},{"given":"Maria Antonia","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}]},{"given":"Jose","family":"Villamarin","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}]},{"given":"Rene Rivera","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, FL, USA"}]},{"given":"Regina","family":"Castaneda","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, FL, USA"}]},{"given":"Dima","family":"Bechenati","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, FL, USA"}]},{"given":"Sima","family":"Fansa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}]},{"given":"Maria D.","family":"Hurtado","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, FL, USA"}]},{"given":"Andres","family":"Acosta","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA"}]},{"given":"Omar M.","family":"Ghanem","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic, Rochester, MN, USA"}]}],"issued":{"date-parts":[[2026,4,20]]},"member":"276","prefix":"10.1097","source":"Crossref","volume":null,"created":{"date-time":"2026-04-20T04:01:35Z","timestamp":1776657695000,"date-parts":[[2026,4,20]]},"indexed":{"date-time":"2026-04-20T04:41:35Z","timestamp":1776660095438,"date-parts":[[2026,4,20]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://journals.lww.com/10.1097/SLA.0000000000007064"}},"subtitle":["A Head-to-Head Comparison in Improvement of Cardiometabolic Risk Profiles"],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","value":"2026-01-27"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","value":"2026-03-27"}],"deposited":{"date-time":"2026-04-20T04:01:36Z","timestamp":1776657696000,"date-parts":[[2026,4,20]]},"issn-type":[{"type":"print","value":"0003-4932"},{"type":"electronic","value":"1528-1140"}],"published":{"date-parts":[[2026,4,20]]},"publisher":"Ovid Technologies (Wolters Kluwer Health)","reference":null,"short-title":[],"update-policy":"https://doi.org/10.1097/lww.0000000000001000","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Annals of Surgery"],"reference-count":0,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,20]]},"references-count":0,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1097/sla.0000000000007064","is_oa":false,"title":"Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy","updated":"2026-04-20T08:06:07+00:00","published_date":"2026-04-20","best_oa_location":null}},"created_at":"2026-05-07T22:50:48.348Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"condition","value":"Atherosclerotic Cardiovascular Disease","value_numeric":null},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"modality","value":"GLP-1 Receptor Agonist","value_numeric":null},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"modality","value":"Metabolic and Bariatric Surgery","value_numeric":null},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"sample_size","value":"n=812","value_numeric":812},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"warning","value":"Baseline imbalance: GLP-1RA patients were older with higher baseline ASCVD risk; multivariable adjustment partially addresses this but residual confounding is likely in this non-randomized design.","value_numeric":null},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"warning","value":"Primary outcomes are estimated (modeled) ASCVD risk scores, not observed cardiovascular events; clinical event validation is absent.","value_numeric":null},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"warning","value":"Specific GLP-1RA agents and MBS procedure types (e.g., sleeve gastrectomy vs. Roux-en-Y) are not detailed in the abstract, limiting subgroup interpretation.","value_numeric":null},{"paper_doi":"10.1097/sla.0000000000007064","tag_type":"warning","value":"The 'practice_changing' flag reflects the superiority of lifetime ASCVD risk reduction with MBS, but should be interpreted cautiously given the retrospective, single-system design.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study compared 1-year changes in estimated 10-year and lifetime ASCVD risk in 812 adults with obesity (BMI ≥30) who underwent metabolic/bariatric surgery (MBS, n=579) or initiated GLP-1RA therapy (n=233) between 2020–2023 within a US tertiary health system.","key_result":"10-year ASCVD risk reduction was similar between MBS and GLP-1RA (-0.8% vs. -1.1%; P=.36), but lifetime ASCVD risk fell significantly more with MBS (-8.6% vs. -1.7%; P<.001). MBS also produced greater weight loss (-27.8% vs. -11.1%) and more favorable LDL and HDL changes; the advantage persisted after multivariable adjustment (β -6.92; 95% CI -9.22 to -4.62).","limitations":"- Retrospective design with baseline imbalances (GLP-1RA patients were older with higher baseline ASCVD risk), which may confound comparisons despite adjustment.\n- Only 12-month follow-up; long-term cardiovascular event data are not available.\n- Outcomes are estimated ASCVD risk scores, not actual cardiovascular events.","practice_takeaway":"Both MBS and GLP-1RA therapy reduce cardiovascular risk in patients with obesity, but MBS delivers substantially larger lifetime ASCVD risk reduction and weight loss at 1 year. Clinicians should consider surgical referral for eligible patients when long-term cardiovascular risk reduction is a priority, while recognizing GLP-1RAs as a meaningful alternative."}}],"initialOffset":4,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Metabolic and Bariatric Surgery"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Metabolic and Bariatric Surgery"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Metabolic and Bariatric Surgery"}}}]]

Papers